Stockreport

Immunovant Provides Update on Graves’ Disease Development Program

Immunovant, Inc.  (IMVT) 
PDF High dose batoclimab achieved 76% response rate in patients uncontrolled on antithyroid drugs (ATDs) at week 12High dose batoclimab achieved 56% ATD-Free response rate i [Read more]